1834 Investment Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

1834 Investment Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,900	Closed	-$3K	–	513
2020 Q4	$3K	Hold	4,900	–	–	﹤0.01%	435
2020 Q3	$11K	Hold	4,900	–	–	﹤0.01%	337
2020 Q2	$18K	Hold	4,900	–	–	﹤0.01%	298
2020 Q1	$19K	Sell	4,900 -150	-3%	-$494	﹤0.01%	303
2019 Q4	$15K	Buy	+5,050	New	+$13.1K	﹤0.01%	351

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

1834 Investment Advisors's BMY.RT Position: Q1 2021 in Review

1834 Investment Advisors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 4,900 shares — an estimated $3K sold.

1834 Investment Advisors first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $19K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

1834 Investment Advisors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
1834 Investment Advisors sold 4,900 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $3K.
1834 Investment Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
1834 Investment Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $19K in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on 1834 Investment Advisors's 13F filing for Q1 2021, filed 14 May 2021.